Heterogeneity between primary colon carcinoma and paired lymphatic and hepatic metastases

Molecular Medicine Reports

Volumn 6, Issue 5, 2012, Pages 1057-1068

  Lan, Huanrong ^a   Jin, Ketao ^a,b   Xie, Bojian ^c   Han, Na ^d   Cui, Binbin ^a   Cao, Feilin ^a   Teng, Lisong ^b  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Colon carcinoma; Functional gene; Genome wide gene expression; Hepatic metastasis; Heterogeneity

Indexed keywords

ADULT; ARTICLE; CASE REPORT; COLON CARCINOMA; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; PRIMARY TUMOR;

ADULT; CARCINOMA; COLONIC NEOPLASMS; DNA PROBES; FEMALE; GENE EXPRESSION; GENOME, HUMAN; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84866460178     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1051     Document Type: Article

References (18)

1. Jin KT, He KF, Teng F, Han N, Li GL, Xu ZZ and Teng LS: Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy? Pers Med 8: 175-182, 2011.
2. Gong Y, Booser DJ and Sneige N: Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103: 1763-1769, 2005. (Pubitemid 40563246)
3. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ and Larsimont D: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036-1043, 2002.
4. Regitnig P, Schippinger W, Lindbauer M, Samonigg H and Lax SF: Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203: 918-926, 2004. (Pubitemid 39089280)
5. Bozzetti C, Personeni N, Nizzoli R, Guazzi A, Flora M, Bassano C, Negri F, Martella E, Naldi N, Franciosi V and Cascinu S: HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 99: 310-315, 2003. (Pubitemid 37248379)
6. Tanner M, Järvinen P and Isola J: Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61: 5345-5348, 2001. (Pubitemid 32694907)
7. Tapia C, Savic S, Wagner U, Schönegg R, Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G, Terracciano L, Feichter G and Bubendorf L: HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9: R31, 2007.
8. Akcakanat A, Sahin A, Shaye AN, Velasco MA and Meric-Bernstam F: Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112: 2352-2358, 2008.
9. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S and Argani P: Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14: 1938-1946, 2008. (Pubitemid 351551102)
10. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16: 790-799, 2010.
11. Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, Camponovo A, Bordoni A, Crippa S, Mazzucchelli L and Frattini M: Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 100: 1087-1094, 2009.
12. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G and Cascinu S: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22: 4772-4778, 2004.
13. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Pierantoni C and Cascinu S: Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. Br J Cancer 97: 92-97, 2007. (Pubitemid 47012100)
14. Sasatomi E, Finkelstein SD, Woods JD, Bakker A, Swalsky PA, Luketich JD, Fernando HC and Yousem SA: Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. Cancer Res 62: 2681-2689, 2002. (Pubitemid 34464122)
15. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Jänne PA and Ahn MJ: Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 4: 809-815, 2009.
16. Jin K, Li G, Cui B, Zhang J, Lan H, Han N, Xie B, Cao F, He K, Wang H, Xu Z, Teng L and Zhu T: Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS One 6: e28384, 2011.
17. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M and Merk J: Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14: 6456-6468, 2008.
18. Jin KT, He KF, Li GL and Teng LS: Personalized cancer therapy using a patient-derived tumor tissue xenograft model: a translational field worthy of exploring further? Pers Med 7: 597-606, 2010.